This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The effectiveness results were derived from the outcomes in the literature. The outcomes were: the vaccination success rate; the accumulated coverage rates of rubella vaccination, which was administered on an individual basis until the age of 3; the group (school) rubella vaccination coverage rates; the natural rubella infection rate at the age of 13; and the school urine test coverage rates.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Five primary studies were included in the review
Methods of combining primary studies
Not carried out.
Investigation of differences between primary studies
Results of the review
The vaccination success rate was 95%.
The accumulated coverage rate of individual rubella vaccination to the age of 3 was approximately 35%.
The group (school) rubella vaccination coverage rate was 70%.
The natural rubella infection rate at the age of 13 was 50%.
The school urine test coverage rate was 97%.
Given these data, the positive rates of rubella antibody detection were predicted for the three vaccination programmes using:
